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Introduction
Matthew Quaife is an assistant professor at the London
School of Hygiene and Tropical Medicine (LSHTM),
UK. His interests are health economics and mathemat-
ical modelling specialising in public health and infectious
disease prevention. Currently, his research projects are
focused on COVID-19 transmission in low- and middle-
income settings, as well as evaluation of tuberculosis
(TB) modelling to study the cost-effectiveness and equity
impact of vaccines and digital adherence technologies.
Shuai Li is a Victorian Cancer Agency Early Career
Research Fellow at the Centre for Epidemiology and Bio-
statistics at the University of Melbourne, Australia. His
research interests are on genetic and epigenetic epidemi-
ology of cancers, twin and family research, and cancer
risk modelling. His main research projects are on devel-
opments of comprehensive risk models for breast cancer,
investigations on the relationships of DNA methylation
and health-related exposures, and applications of twin
and family designs for causation assessment.
Drs. Quaife and Li are both recent members of the
editorial board scheme for BMC Medicine, which in-
volves working closely with our in-house editors to en-
sure that all manuscripts are subject to the same
editorial standards and journal policies. Editorial Board
Members (EBMs) handle manuscripts within their areas
of expertise and oversee aspects of the peer review
process from submission to acceptance.
What is the most rewarding experience working as an
EBM for BMC Medicine?
MQ: I really believe in the journal’s mission to make
high quality research available open access. I previously
had really good experiences with the journal as an au-
thor, both successful and unsuccessful - though the lat-
ter was still productive. I find it quite rewarding trying
to contribute to the same robust but professional and
friendly communication with authors about their manu-
scripts, and it’s incredibly satisfying when a paper you
have managed through the system is finally published.
SL: I think the most rewarding experience is that I get
a deeper understanding the editorial process of the sub-
mitted manuscripts. A manuscript needs to fit the scope
and pass the threshold in order to sent out for external
review – the first step for getting published. It was inter-
esting to learn about this process.
Did you find anything surprising or unexpected when
learning about the editorial process?
MQ: I was previously on the editorial board of a differ-
ent journal which published slightly less influential work,
so the switch to thinking through whether submissions
are of excellent scientific quality and policy relevance
has been an interesting one. Not just assessing if manu-
scripts merit publication somewhere, but publication
here. Otherwise all surprises have been very quickly miti-
gated by the excellent support we receive from the rest
of the editorial team.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: matthew.quaife@lshtm.ac.uk; shuai.li@unimelb.edu.au
1Centre for Mathematical Modelling of Infectious Diseases and TB Modelling
Group, Department of Infectious Disease Epidemiology, Faculty of
Epidemiology and Population Health, London School of Hygiene and
Tropical Medicine, Keppel Street, London WC1E 7HT, UK
2Centre for Epidemiology and Biostatistics, Melbourne School of Population
and Global Health, The University of Melbourne, 207 Bouverie Street, Carlton,
Melbourne, Victoria 3053, Australia
Full list of author information is available at the end of the article
Quaife and Li BMC Medicine          (2021) 19:234 
https://doi.org/10.1186/s12916-021-02102-5
SL: I was impressed by the scope and threshold of the
journal. The journal covers all topics related to medicine
and has a very inclusive topic selection. The editorial team
knows well about the research field of the manuscripts I
handled and similar publications, so they can always give
critical assessments to the submissions. They have a high
threshold on the quality of papers to be published.
What challenges did you find with handling a manuscript
through peer review?
MQ: Finding reviewers! Particularly during the pandemic,
it’s been such a busy time for infectious disease modellers
and economists that when an interesting – COVID-19 or
non-COVID-19 – paper appears, it has proven quite tricky
to find people with enough time to review to the right level.
SL: I find the most challenging thing is to find suitable
reviewers quickly. I am familiar with the research field of
the manuscripts I handled, so for some manuscripts I
know who would give a good review; however, the po-
tential reviewers that come to mind initially may have
conflicts of interest with the authors, or are too busy to
review. Sometimes I need to invite many reviewers with
the help of the editorial team to get enough agreed re-
viewers, and sometimes the process takes a long time.
How do you find managing manuscripts that are
sometimes outside of your research focus?
MQ: Initially I found this quite daunting considering papers
which had a different disease focus from my work, or using
methods slightly outside of those I use on a daily basis. Here
I have benefitted from input from my editorial colleagues
who are able to give initial opinions based on similar papers
which have come across BMCMedicine’s desk, or have been
published elsewhere. We also have a wonderful network of
peer reviewers, who give incredibly valuable and insightful
comments on manuscripts. If in doubt, I am always inclined
to reach out to reviewers for their input.
SL: Fortunately, the manuscripts I have handled are all
within my research focus, so I have not had the experience
mentioned in the question yet. However, if that happens
in the future, I think I will firstly read some publications
to get myself familiar with relevant research field, and try
to manage the manuscripts with the help of the editorial
team. If I feel it’s not easy to do this, I would feel comfort-
able to discuss this with the editorial team, and ask them
to find a more suitable member to handle.
How does understanding the editorial process help you
as a researcher?
MQ: It’s been really valuable seeing the other side of the
process. The things which editors look for in a poten-
tially influential manuscript aren’t necessarily the things
that I was focusing on when writing papers, and I have
really learnt the importance of a good abstract! No
longer is it the thing I write last, just before pressing
submit…
SL: I think I have learned two major things. The first
thing is that the in-house editorial team has their own
threshold for the manuscripts they are interested in pub-
lishing. The threshold depends on many factors, such as
the quality and topic of the study, and the potential im-
pact of the study. The second thing is that the peer re-
view process can sometimes take very long time,
especially when there are delays in finding suitable re-
viewers and reviewers returning their comments. The
editors are unwilling to see this delay as well, and they
are working hard and try their best to speed up. So as a
researcher understanding this process, and understand-
ing the issues in sending across timely and helpful re-




All authors read and approved the final manuscript.
Funding
MQ acknowledges funding from the Bill and Melinda Gates Foundation (INV-
001754).
SL is supported by the Victorian Cancer Agency Early Career Research
Fellowship (ECRF19020), by grant 1187896 awarded through the 2019
Priority-driven Collaborative Cancer Research Scheme and funded by Cure
Cancer with the support of Cancer Australia, and by grant 2004702 awarded
through the 2020 Priority-driven Collaborative Cancer Research Scheme and
funded by Cancer Australia.
Availability of data and materials
Not applicable
Declarations





MQ and SL have no conflicts of interest to declare.
Author details
1Centre for Mathematical Modelling of Infectious Diseases and TB Modelling
Group, Department of Infectious Disease Epidemiology, Faculty of
Epidemiology and Population Health, London School of Hygiene and
Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 2Centre for
Epidemiology and Biostatistics, Melbourne School of Population and Global
Health, The University of Melbourne, 207 Bouverie Street, Carlton, Melbourne,
Victoria 3053, Australia. 3Centre for Cancer Genetic Epidemiology,
Department of Public Health and Primary Care, University of Cambridge,
Cambridge, UK. 4Precision Medicine, School of Clinical Sciences at Monash
Health, Monash University, Melbourne, Australia.
Received: 18 August 2021 Accepted: 18 August 2021
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Quaife and Li BMC Medicine          (2021) 19:234 Page 2 of 2
